Hema Malini Hosts 2nd Prayer Meet for Dharmendra in Mathura, Pays Tribute to Late Actor’s Legacy
: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications
: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression).
Provide a breakdown of the used by the researchers in this study. Which of these would be most helpful for you?
: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group.
The researchers analyzed a large group of 616 patients with who were treated with ibrutinib. The goal was to see if the high success rates found in clinical trials were mirrored in everyday medical practice across various hospitals. Key Findings and Statistics
: Investigating approaches where patients only take the drug for a set period, especially if they achieve a complete response, to avoid unnecessary long-term exposure and side effects. If you'd like, I can:
The search for a "616 KB" article points directly to a significant medical study titled